The drug, which will be marketed under the brand name Covifor, will likely be priced at 5,000 to 6,000 rupees ($66-$79) for a 100 milligram dose, Hetero said.
India’s Cipla Ltd has also received approval from the Drug Controller General of India (DGCI) to manufacture and market the drug, according to a report https:// in Indian Express.
Cipla and DGCI were not immediately available for comment.
Gilead Sciences Inc (NASDAQ:GILD) signed non-exclusive licensing pacts last month with five generic drugmakers based in India and Pakistan to expand the supply of its COVID-19 treatment.
The pacts allow Jubilant Life Sciences Ltd, Cipla, Hetero Labs, Mylan (NASDAQ:MYL) NV and Ferozsons Laboratories Ltd to make and sell the drug in 127 countries.